LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024 CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3% MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops MT
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Dividend for the Year 2022, Payable on 22 May 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Dividend for 2022 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022 CI
Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022 CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.
More charts
SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Company’s main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
145.4
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300573 Stock
  4. News Shenyang Xingqi Pharmaceutical Co.,Ltd.
  5. Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%